Last reviewed · How we verify
NCT05076331
Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
trial testing PI-2620 tracer for Tau PET scan in Alzheimer Disease in 3,000 participants. Status unknown.
30 August 2023
Quick facts
| Lead sponsor | University of North Texas Health Science Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 20 April 2021 |
| Primary completion | 30 August 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PI-2620 tracer for Tau PET scan
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
University of North Texas Health Science Center
Who can join
50 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this project is to study the aging brain among participants enrolled in the Health and Aging Brain Study: Health Disparities project . There are a number of things that can influence how people think as they age, including diabetes, depression, as well as our biology. In this study, the investigators seek to study the aging brain by using brain PET scans that create detailed pictures of the brain.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05076331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other University of North Texas Health Science Center trials
Trials by the same sponsor.
- NCT04978129 — Enhancing Quality in Protective Strategies · NA · completed
- NCT06025630 — Targeting Endoplasmic Reticulum Stress in Human Hypertension · Phase 1, PHASE2 · recruiting
- NCT05495087 — IHT for Mild Cognitive Impairment · NA · unknown
- NCT04333966 — Parental Research on Interventions for Social Media · NA · completed
- NCT05706181 — Heat Therapy, Functional Capacity, and Vascular Health in Older Adults · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05076331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Texas Health Science Center
- Last refreshed: 13 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05076331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing